New drug combo aims to stop liver Cancer's return
NCT ID NCT04639180
First seen Jan 05, 2026 · Last updated May 23, 2026 · Updated 17 times
Summary
This phase 3 trial tests whether a combination of two drugs (camrelizumab and rivoceranib) can prevent liver cancer from returning in patients who have a high risk of recurrence after surgery or ablation. About 687 participants will either receive the drug combination or be closely monitored without treatment. The study measures how long patients stay cancer-free and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Guangxi Medical University Affiliated Tumor Hospital
Nanjin, Guangzhou, China
-
Guizhou Cancer Hospital
Guiyang, Guizhou, China
-
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.